Pfizer Inc Analysis – September 2015 Update $PFE

Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company or by reviewing the 10 Most Undervalued Companies for the Defensive Investor – August 2015.  By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a stock analysis showing a specific look at how Pfizer Inc (PFE) fares in the ModernGraham valuation model.

Company Profile (obtained from Google Finance): Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.


To read the details of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.

Premium members can view a full ModernGraham valuation of the company and have access to download a PDF version of the valuation for easy reference. Here is a free sample valuation pdf, and here is a post detailing what can be found within each individual company’s valuation.


Downloadable PDF version of this valuation:

ModernGraham Valuation of PFE – September 2015

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $202,942,811,828 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 2.14 Pass
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Pass
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 26.44% Fail
6. Moderate PEmg Ratio PEmg < 20 16.87 Pass
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 3.06 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 2.14 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 0.97 Pass
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass

Stage 2: Determination of Intrinsic Value

PFE value Chart September 2015

EPSmg $1.94
MG Growth Estimate 9.72%
MG Value $54.29
Opinion Undervalued
MG Value based on 3% Growth $28.18
MG Value based on 0% Growth $16.52
Market Implied Growth Rate 4.19%
Current Price $32.79
% of Intrinsic Value 60.40%

Pfizer Inc qualifies for the Enterprising Investor but not the more conservative Defensive Investor.  The Defensive Investor is concerned with the insufficient earnings growth over the last ten years, and the high PB ratio.  The Enterprising Investor has no initial concerns.  As a result, all Enterprising Investors following the ModernGraham approach based on Benjamin Graham’s methods should feel comfortable proceeding with further research into the company.

As for a valuation, the company appears to be undervalued after growing its EPSmg (normalized earnings) from $1.18 in 2011 to an estimated $1.94 for 2015.  This level of demonstrated earnings growth outpaces the market’s implied estimate of 4.19% annual earnings growth over the next 7-10 years.  As a result, the ModernGraham valuation model, based on Benjamin Graham’s formula, returns an estimate of intrinsic value above the price.

The next part of the analysis is up to individual investors, and requires discussion of the company’s prospects.  What do you think?  What value would you put on Pfizer Inc. (PFE)?  Where do you see the company going in the future?  Is there a company you like better?  Leave a comment on our Facebook page or mention @ModernGraham on Twitter to discuss.

Stage 3: Information for Further Research

PFE Charts September 2015

Net Current Asset Value (NCAV) -$6.77
Graham Number $20.68
PEmg 16.87
Current Ratio 2.14
PB Ratio 3.06
Dividend Yield 3.29%
Number of Consecutive Years of Dividend Growth 5


Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Total Current Assets $51,715,000,000
Total Current Liabilities $24,143,000,000
Long-Term Debt $26,729,000,000
Total Assets $160,878,000,000
Intangible Assets $74,995,000,000
Total Liabilities $93,984,000,000
Shares Outstanding (Diluted Average) 6,243,000,000

Earnings Per Share History

Next Fiscal Year Estimate $1.75
Dec14 $1.42
Dec13 $3.19
Dec12 $1.94
Dec11 $1.27
Dec10 $1.02
Dec09 $1.23
Dec08 $1.20
Dec07 $1.17
Dec06 $2.66
Dec05 $1.09
Dec04 $1.49
Dec03 $0.54
Dec02 $1.46
Dec01 $1.22
Dec00 $0.59
Dec99 $0.82
Dec98 $0.85
Dec97 $0.57
Dec96 $0.50
Dec95 $0.42

Earnings Per Share – ModernGraham History

Next Fiscal Year Estimate $1.94
Dec14 $1.95
Dec13 $2.05
Dec12 $1.43
Dec11 $1.18
Dec10 $1.24
Dec09 $1.39
Dec08 $1.49
Dec07 $1.55
Dec06 $1.64
Dec05 $1.14
Dec04 $1.13
Dec03 $0.95
Dec02 $1.10
Dec01 $0.88
Dec00 $0.69
Dec99 $0.71

Recommended Reading:

Other ModernGraham posts about the company

10 Undervalued Companies for the Enterprising Dividend Stock Investor – August 2015
The Best Companies of the Pharmaceuticals Industry – August 2015
5 Undervalued Dow Stocks to Research – August 2015
5 Undervalued Companies with a Low Beta – August 2015
5 Undervalued Dow Stocks to Research – July 2015

Other ModernGraham posts about related companies

Johnson & Johnson Analysis – September 2015 Update $JNJ
Celgene Corporation Analysis – September 2015 Update $CELG
Allergan PLC Analysis – August 2015 Update $AGN
The Best Companies of the Pharmaceuticals Industry – August 2015
Alexion Pharmaceuticals Inc. Analysis – August 2015 Update $ALXN
Akorn Inc. Analysis – Initial Coverage $AKRX
Zoetis Inc. Analysis – July 2015 Update $ZTS
Mallinckrodt PLC Analysis – Initial Coverage $MNK
Biogen IDEC Inc. Analysis – July 2015 Update $BIIB
Vertex Pharmaceuticals Analysis – July 2015 Update $VRTX


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.






Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.